Ritu Salani, MD

Ritu Salani, MD, MBA, of the David Geffen School of Medicine at UCLA, explains to Rachel N. Grisham, MD, of Memorial Sloan Kettering Cancer Center, how she describes the mechanism of relacorilant to patients with platinum-resistant ovarian cancer.

Ritu Salani, MD, MBA, of the David Geffen School of Medicine at UCLA, and Rachel N. Grisham, MD, of Memorial Sloan Kettering Cancer Center, discuss how to set expectations when a patient with platinum-resistant ovarian cancer tests positive for a biomarker.

Explore the latest platinum-resistant ovarian cancer therapies, from biomarkers to sequencing, including new FDA-approved regimens like mirvetuximab and relicorlant.

Explore the latest platinum-resistant ovarian cancer therapies, from biomarkers to sequencing, including new FDA-approved regimens like mirvetuximab and relicorlant.

Panelists discuss how the evolving role of antibody-drug conjugates (ADCs) in treating gynecologic cancers, including ovarian, endometrial, and cervical cancers, offers exciting opportunities for more personalized treatments that could improve progression-free survival and quality of life, while addressing challenges in therapy sequencing, toxicity management, and biomarker-driven approaches.

Panelists discuss how early detection and proactive management of ocular toxicities associated with mirvetuximab soravtansine, including regular screening, eye exams, and collaboration with ophthalmologists, are essential for ensuring timely intervention and minimizing long-term complications such as cataracts, particularly as the drug transitions to broader clinical use.

Panelists discuss how managing interstitial lung disease (ILD) associated with antibody-drug conjugates (ADCs) such as mirvetuximab soravtansine requires proactive monitoring, including baseline and ongoing chest CT scans, early intervention with steroids, and close collaboration with pulmonologists and radiologists to minimize risks and ensure patient safety during treatment.

Panelists discuss how the rapid evolution of antibody-drug conjugates (ADCs) in gynecologic cancers, including promising agents such as mirvetuximab soravtansine and toriluzumab, is generating excitement, with a focus on optimizing treatment sequencing and exploring combinations of ADCs to improve outcomes for patients with platinum-resistant ovarian cancer.

Panelists discuss how mirvetuximab soravtansine (MIRV), an antibody-drug conjugate, has become a vital treatment for platinum-resistant ovarian cancer, highlighting its effectiveness in patients with high folate receptor alpha expression, its well-tolerated profile with manageable toxicities, and the potential for expanding its use into earlier treatment lines and combination therapies.

Panelists discuss how the accelerated approval of trastuzumab deruxtecan (T-DXd) offers a promising new treatment option for patients with HER2-positive gynecologic cancers, while highlighting the need for confirmatory trials to refine patient selection, testing methodologies, and treatment sequencing strategies, as well as managing varying patient responses and addressing tolerability concerns.

Panelists discuss how the recent accelerated approval of trastuzumab deruxtecan (T-DXd) in HER2-expressing endometrial cancer prompts critical questions about treatment sequencing, as clinicians weigh efficacy, toxicity, and emerging evidence to personalize therapy in a rapidly evolving gynecologic oncology landscape.

Panelists discuss how evolving insights into HER2 expression—drawn from parallels with breast cancer—highlight the need for standardized HER2 testing in gynecologic oncology, as emerging data on HER2-low status and variability in current testing approaches underscore both the therapeutic potential of antibody-drug conjugates (ADCs) and the challenges of implementing precision medicine in this setting.

Panelists discuss how antibody-drug conjugates (ADCs) and molecular testing are reshaping treatment strategies in ovarian and endometrial cancers by enabling more personalized, targeted care, while addressing practical challenges such as tissue limitations, tumor heterogeneity, and the evolving role of liquid biopsy in optimizing diagnostic accuracy.

Ritu Salani, MD, MBA, discusses considerations in clinical trial design and the evolving role of HER2-targeted ADCs in gynecologic malignancies.

Ritu Salani, MD, MBA, discusses the management of ocular toxicities associated with mirvetuximab soravtansine in ovarian cancer.

Ritu Salani, MD, MBA, discusses pathways implicated in low-grade serous ovarian cancer that may be viable for targeted therapy development.

Martin Dietrich, MD, PhD, and Ritu Salani, MD, share their outlook on the future roles of HER2-directed ADCs in gynecological cancers and other solid tumors, highlighting the necessity for additional research to provide further understanding in these areas.

Ritu Salani, MD, provides expert insights regarding HER2 testing in patients with gynecological cancers, emphasizing the need for standardization in testing practices and greater clarity surrounding the incidence of HER2 positivity across gynecological cancers.

Ritu Salani, MD, highlights impactful findings from the DESTINY-PanTumor02 study in patients with cervical cancer, highlighting the promising role of HER2-directed ADCS in this treatment space.

Ritu Salani, MD, discusses impactful efficacy signals from T-DXd in the DESTINY-PanTumor02 study for endometrial cancer, marking a potential breakthrough in this treatment field.

Ritu Salani, MD, discusses the de-escalation of therapy and unmet needs within the landscape of gynecologic oncology.

Ritu Salani, MD, presents an outline of the treatment landscape for ovarian cancer and underscores encouraging data from the DESTINY-PanTumor02 study, showcasing promising results in this treatment setting.

Martin Dietrich, MD, PhD, discusses the role of HER2 ADCs in GI cancers, reviewing key data from DESTINY-Gastric and DESTINY-CRC trials.

Martin Dietrich, MD, PhD, examines the safety and efficacy of HER2-directed ADCs in NSCLC, emphasizing significant differences in response associated with HER alterations.

Martin Dietrich, MD, PhD, offers a comprehensive review of the efficacy and safety of HER2 ADCs in breast cancer, underscoring their substantial impact on treatment practices in both HER2+ and HER2-low.

Martin Dietrich, MD, PhD, reflects on the lessons and insights gleaned from HER2 in breast cancer, examining their influence on the development of treatment approaches utilizing HER2-targeted therapies in other solid tumors.

Martin Dietrich, MD, PhD, presents a thorough analysis of HER2 as a pan-tumor biomarker, underscoring its universal importance in the field of oncology.

Experts Ritu Salani, MD, MBA, and Bhavana Pothuri, MD, explore the significance of enrolling diverse patients in clinical trials and the pivotal role of community settings in advancing endometrial cancer research and treatment.

Delve into the exciting developments in endometrial cancer treatment, including HER2 antibody drug conjugates, checkpoint inhibitors, and the promising impact of these therapies in the quest to reduce chemotherapy use.

Explore the groundbreaking shift in frontline treatment for endometrial cancer, driven by recent data from trials like RUBY and GY018, highlighting the significant impact of checkpoint inhibitors in patients with mismatch repair deficiency.